Meet Deborah, living with relapsed/refractory CLL
About Deborah
- 74 years old
- Over the past 6 weeks, symptoms returned (especially night sweats and fatigue) for the first time since frontline treatment
- ECOG PS 1
Medical history
- Responded well to CIT frontline – first treatment at 66 years
- Complete response with 6 cycles of FCR frontline and 8-year remission
- Mild CV disease (otherwise healthy)
Physical examination
- Small lymph nodes of 2 to 3 cm that were palpable in all peripheral areas
Laboratory results
- Absolute lymphocyte count: 120 x109/L
- Haemoglobin: 96 g/dL
- Platelets: 60,000 /µL
- FISH: del(11q) but no del(17p) No TP53 mutations were present
This is a fictional patient example
![Choose IMBRUVICA® first for patients like Deborah[^1][^2] [^1]: Eichhorst B, <em>et al.</em> Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol.</em> 2021;32(1):23-33. [^2]: Munir T, <em>et al.</em> Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <em>Am J Hematol.</em> 2019;94(12):1353–1363.](https://eu-images.contentstack.com/v3/assets/blt6b8ca7f1bf9e5733/blt884782257b74875d/636ba8b32d8c1537aef2b352/feature_banner_2.png?width=1920&height=360&format=webp&quality=50)
Choose IMBRUVICA® first for patients like Deborah[1][2]
Only IMBRUVICA® offers long-term survival benefits in patients with R/R CLL including those who respond poorly or are unsuitable for CIT[2][3][4]
IMBRUVICA® could offer patients with R/R CLL more than 4 years of PFS[3]
HELIOS: PFS with IMBRUVICA® + BR vs. placebo + BR[4]
Median PFS for IMBRUVICA® + BR at final analysis was 65.1 months vs. 14.3 months for placebo + BR arm[4]
Adapted from Fraser G, et al. 2020.[4]
Final 5-year findings from the phase III HELIOS study of IMBRUVICA® + BR in patients with relapsed/refractory CLL/SLL without del(17p) assessing PFS and OS (N=578).[4]
RESONATE: PFS with IMBRUVICA® vs. ofatumumab[2]
Median PFS was 44.1 months with IMBRUVICA® vs. 8.1 months with ofatumumab[2]†
Adapted from Munir T, et al. 2019.[2]
Final analysis from RESONATE: RESONATE is a randomised phase III study investigating the efficacy of IMBRUVICA® over ofatumumab in 391 patients with relapsed/refractory CLL/SLL, including those with high-risk features.[2]
Choose IMBRUVICA® at earlier vs. later lines of therapy for improved PFS[2]
- IMBRUVICA® in early lines of therapy offers improved outcomes for patients with CLL[2]
- Median PFS not reached with IMBRUVICA® for patients with 1 prior LOT (95% CI, 44.4-NE) vs. 67.3 months for patients with 2 prior LOTs (95% CI, 36.0–NE)[2]†
![IMBRUVICA® offers the reassurance of the longest follow-up of any novel targeted therapy in R/R CLL[^3] [^3]: Byrd J, <em>et al.</em> Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase lb/ll PCYC-1102 study. <em>Clin Cancer Res.</em> 2020;26(15):3918–3927.](https://eu-images.contentstack.com/v3/assets/blt6b8ca7f1bf9e5733/bltdf04b706e8f95573/636ba8e045083c3ef09bd53d/feature_banner_2.png?width=1920&height=360&format=webp&quality=50)
IMBRUVICA® offers the reassurance of the longest follow-up of any novel targeted therapy in R/R CLL[3]
Patients with R/R CLL treated with IMBRUVICA® have been followed for up to 8 years[3]*
CLL patient subgroups
uIGHV patients
Genetic aberration patients
Fit patients
Relapsed / refractory patients
Back to IMBRUVICA® studies
Back to IMBRUVICA® efficacy
*Median follow-up: 82 months in R/R CLL, median time on IMBRUVICA®: 39 months in R/R CLL.[3]
†Median follow-up 65.3 months.[2]
BR=bendamustine + rituximab; CI=confidence interval; CLL=chronic lymphocytic leukaemia; CIT=chemoimmunotherapy; CV=cardiovascular; HR=hazard ratio; ECOG PS=Eastern Cooperative Oncology Group performance status; FCR=fludarabine + cyclophosphamide + rituximab; FISH=Fluorescence In Situ Hybridisation; LOT=line of therapy; NE=not evaluable; OS=overall survival; PFS=progression-free survival; R/R=relapsed/refractory; SLL=small lymphocytic lymphoma.
